Idorsia Ltd (SWX: IDIA)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 136.07M |
| Revenue (ttm) | 74.12M |
| Net Income (ttm) | -296.43M |
| Shares Out | 188.33M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,403,751 |
| Open | 0.759 |
| Previous Close | 0.759 |
| Day's Range | 0.612 - 0.790 |
| 52-Week Range | 0.612 - 3.700 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemor... [Read more]
Financial Performance
In 2023, Idorsia's revenue was 152.39 million, an increase of 56.93% compared to the previous year's 97.10 million. Losses were -297.92 million, -64.01% less than in 2022.
Financial StatementsNews
Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension
Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients wh...
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of syst...
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia's dual orexin receptor antagonist for the treatment of adults wi...
Amended terms of Idorsia's 2024 convertible bonds become effective
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal wa...
Idorsia Ltd (IDRSF) Q2 2024 Earnings Call Transcript
Idorsia Ltd (OTC:IDRSF) Q2 2024 Earnings Conference Call July 27, 2024 9:00 AM ET Company Participants Andrew Weiss - Senior Vice President, Head of Investor Relations & Corporate Communications Andre...
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
Allschwil, Switzerland – July 1, 2024 Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adul...
Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality' category
Allschwil, Switzerland – June 21, 2024 Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize i...
Idorsia holds its Annual General Meeting of Shareholders
Allschwil, Switzerland – June 13, 2024 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Direc...
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
Allschwil, Switzerland – May 23, 2024 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting ...
Idorsia Ltd (IDRSF) Q1 2024 Earnings Call Transcript
Idorsia Ltd (OTC:IDRSF) Q1 2024 Results Conference Call May 21, 2024 8:00 AM ET Company Participants Andrew Weiss - SVP, Head of Investor Relations & Corporate Communications Jean-Paul Clozel - Chief ...
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of Directors Mathieu Simon to stand for re-election to the Board – taking o...
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023.
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same ...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8'000'000 Idorsia shares.
Idorsia publishes an invitation to a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, ...
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website Bondholder meeting now pla...
Idorsia takes steps to address short-term liquidity needs
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of ...
Idorsia: Aprocitentan Approval Is A Vital News
Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns. FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales ...
Idorsia thanks Guy Braunstein for his years of service as he retires
Allschwil, Switzerland – March 22, 2024 Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development an...
US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult pati...
US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult pati...
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creation The company is focused on extending the cash runway beyond th...
Idorsia Ltd (IDRSF) First Nine-Month 2023 Earnings Call Transcript
Idorsia Ltd (OTC:IDRSF) First Nine-Month 2023 Earnings Conference Call October 24, 2023 9:00 AM ET Company Participants Andrew Weiss – Senior Vice President, Head of Investor Relations & Corporate Com...
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023.